Gamida Cell Ltd

Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will participate in two upcoming investor conferences in January: H.C. Wainwright Bioconnect 2021 Conference, January 11-14, 2021. Company presentation will be available for on-demand viewing at 6:00 a.m. ET on Monday, January 11, 2021. 15th Annual Stern IR Corporate Access Event, January 11-14, 2021.

Gamida Cell to Present at Upcoming January Investor Conferences

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previously announced public offering closed on December 21, 2020. The total number of ordinary shares sold by the Company in the offering was 9,343,750, inclusive of the full exercise of the underwriters' option to purchase up to an additional 1,218,750 shares, at the public offering price of $8.00 per share, l

Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotec

Gamida Cell Added to NASDAQ Biotechnology Index

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a follow-on public offering of 8,125,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $65.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Gamida Cell has granted the underwriters a 30-day opti

Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the company conducted a Type B Meeting for omidubicel with the U.S. Food and Drug Administration (FDA) on Friday, December 11, 2020. During the meeting, the FDA provided encouraging feedback regarding the Phase 3 study of omidubicel pertaining to the pre-specified primary and secondary endpoints. The FDA also recom

Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel

Early data for this company's natural killer cells is drawing lots of attention.

Why Is Everyone Talking About Gamida Cell Stock?

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today will be providing an update on the Phase 3 clinical study of omidubicel, commercial readiness plan and pipeline at its virtual Pipeline Deep Dive event. “Our goal with omidubicel is to revolutionize the field of bone marrow transplantation and bring a potentially curative cell therapy option to thousands of patients who are in ne

Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start BLA Submission by End of 2020

Hookipa Pharma Inc

Gamida Cell (NASDAQ: GMDA) shares are trading higher on Monday following the company's Saturday GDA-201 presentation at the American Society of Hematology Annual Meeting. Gamida Cell is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases.

Why Gamida, Scpharmaceuticals And Hookipa Are Moving Today

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced in an oral presentation the updated and expanded results from a Phase 1 clinical study of GDA-201, an investigational, natural killer (NK) cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), at the 62nd American Society of Hematology (ASH) Annual Meeti

Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that it will host a virtual event discussing the company's pipeline, including omidubicel, an advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of a bone marrow transplant, and GDA-201, an investigational, natural killer (NK) cell-based cancer immunotherap

Gamida Cell to Host Virtual Pipeline Deep Dive

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Chief Executive Officer of Gamida Cell, will present at two virtual conferences in December: Evercore ISI 3rd Annual HealthCONx Conference, fireside chat at 12:10 p.m. ET on December 3, 2020 Piper Sandler 32nd Annual Healthcare Conference, on December 1st-3rd, 2020. Company fireside chat will be available t

Gamida Cell to Present at Upcoming Conferences

Gamida Cell Ltd (GMDA) CEO Julian Adams on Q3 2020 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for the quarter ended September 30, 2020. The company also highlighted progress with omidubicel, an advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of bone marrow transplant, and GDA-201, a natural killer (NK) cell immunotherapy

Gamida Cell Reports Third Quarter 2020 Financial Results and Provides Company Update

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that updated data from the ongoing Phase 1 clinical study of GDA-201, an investigational, natural killer (NK) cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma, will be presented in an oral presentation at the American Society of Hematology (ASH) 62nd Annual Meeting, which is being held virtually from December 5-8, 2020. NK cell immu

Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chief executive officer of Gamida Cell, will present at the H.C. Wainwright 6th Annual Israel Conference on Thursday, November 12, 2020 at 11:00 a.m. ET. A live webcast of the presentation will be available in the “Investors & Media” section of the Gamida Cell website, www.gamida-cell.com, and w

Gamida Cell to Present at H.C. Wainwright 6th Annual Israel Conference

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell announced that it will report its third quarter 2020 financial results and provide a company update on November 10, 2020.

Gamida Cell Announces the Date of Its Third Quarter 2020 Financial Results and Webcast

Gamida Cell recently executed a secondary at $4.50 a share on the back of positive Phase 3 clinical data for its lead asset. The cell therapy biotech now trades at half its 2018 post IPO price despite a likely approval and launch of omidubicel in 2021.

Greenlighting Gamida Cell

BOSTON & MINNEAPOLIS--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell and Be The Match BioTherapies® today announced an expansion of their strategic collaboration for investigational omidubicel.

Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration

Gamida Cell (GMDA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Gamida Cell (GMDA) Jumps: Stock Rises 8.4%

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12 - 16, 2020.

Gamida Cell to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell announced that its Phase 3 clinical study of omidubicel in bone marrow transplant met all three secondary endpoints.

Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell today announced data from an observational study being presented at the virtual Cord Blood Connect Meeting.

Gamida Cell Presents Analysis of Observational Data Demonstrating the Impact of Donor Age in Hematopoietic Stem Cell Transplant Outcomes at the Virtual Cord Blood Connect Meeting

BOSTON--(BUSINESS WIRE)---- $GMDA--Gamida Cell will participate in three upcoming virtual investor conferences in September.

Gamida Cell to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell will host a two-part virtual miniseries in September focused on key topics related to its investigational cell therapy omidubicel.

Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September

BOSTON--(BUSINESS WIRE)---- $GMDA--Gamida Cell will webcast its Annual Meeting of Stockholders on Thursday, September 10, 2020, at 10:00 a.m. ET.

News for Gamida Cell Ltd Stock (GMDA)